Results 271 to 280 of about 4,590,611 (322)

Astrocytic PERK Deficiency Drives Prefrontal Circuit Dysfunction and Depressive‐Like Behaviors

open access: yesAdvanced Science, EarlyView.
Chen et al. show that the endoplasmic reticulum (ER) stress sensor PERK is downregulated in prefrontal cortex (PFC) astrocytes in major depressive disorder and in chronic‐stress mouse models. In young mice, astrocyte‐specific PERK loss reduces the synaptogenic cue thrombospondin‐1 (TSP1), leading to synaptic and circuit deficits and depressive‐like ...
Kai Chen   +8 more
wiley   +1 more source

Microstructural Insights Into LATP Ceramic Nanofibers for High‐Performance Quasi‐Solid‐State Batteries

open access: yesAdvanced Science, EarlyView.
A sustainable electrospinning technique produces LATP ceramic nanofibers that form continuous Li⁺‐conductive pathways within composite solid electrolytes. The resulting quasi‐solid‐state batteries combine the strength of ceramic nanofibers with the flexibility of polymers, delivering high critical current density and excellent rate performance at room ...
Sivaraj Pazhaniswamy   +3 more
wiley   +1 more source

IGZO‐Based First Spike Timing Tactile Encoders and Coupling‐Enhanced Transistor Synapses for Efficient Spiking Neural Networks

open access: yesAdvanced Science, EarlyView.
Here, a bioinspired light‐accelerated neuromorphic system that seamlessly links tactile sensing, first‐spike‐timing (FST) encoding, and light–electric synaptic learning. Pressure stimuli trigger FST spikes in dual‐gate PDTFTs, while GaOx/IGZO hetero‐synapses exhibit enhanced memory under optical–electrical co‐activation, enabling spiking neural ...
Dan Cai   +9 more
wiley   +1 more source

Promoting Autophagy Mitigates Stress‐Induced Remodeling in Patient iPSC‐CMs with the Phospholamban R9C Mutation

open access: yesAdvanced Science, EarlyView.
The Phospholamban (PLN) R9C mutation reduces SERCA2a binding, increasing calcium recycling and baseline contractility. However, the excess of free PLN promotes pentamer formation, limiting phosphorylation and blunting β‐adrenergic signaling. Under cardiac stress, enhanced functional demands overwhelm proteostasis in PLN R9C cells, leading to misfolded ...
Qi Yu   +10 more
wiley   +1 more source

Long-term depression.

Annual Review of Neuroscience, 1989
LTD has now been established as a synaptic plasticity specific to the cerebellum. Cellular and molecular mechanisms of LTD have been elucidated to some extent, but still a number of questions are left open. The most crucial question may concern its time course, as to how long the LTD lasts beyond the limit of the present maximum observation time of 3 ...
Masao Ito
semanticscholar   +3 more sources

Long-term depression in the CNS

Nature Reviews Neuroscience, 2010
Long-term depression (LTD) in the CNS has been the subject of intense investigation as a process that may be involved in learning and memory and in various pathological conditions. Several mechanistically distinct forms of this type of synaptic plasticity have been identified and their molecular mechanisms are starting to be unravelled.
G. Collingridge   +3 more
semanticscholar   +3 more sources

Long-term depression in hippocampus.

Annual Review of Neuroscience, 1996
Long-term depression (LTD) is a lasting decrease in synaptic effectiveness that follows some types of electrical stimulation in the hippocampus. Two broad types of LTD may be distinguished. Heterosynaptic LTD can occur at synapses that are inactive, normally during high-frequency stimulation of a converging synaptic input.
M. Bear, W. Abraham
semanticscholar   +3 more sources

Long-Term Synaptic Depression

Annual Review of Neuroscience, 1995
It is widely assumed that long-term changes in synaptic strength underlie information storage in the brain and, ultimately, behavioral memory. Recent years have seen a major effort to identify and analyze electrophysiological model systems in which particular patterns of neural activity give rise to such enduring changes.
D J, Linden, J A, Connor
openaire   +3 more sources

Long-term safety of ketamine and esketamine in treatment of depression

Expert Opinion on Drug Safety, 2022
Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019.
Sina Nikayin   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy